Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Long Term Response to Levodopa in Parkinson's Disease.

Gupta HV, Lyons KE, Wachter N, Pahwa R.

J Parkinsons Dis. 2019;9(3):525-529. doi: 10.3233/JPD-191633.

PMID:
31205007
2.

Old Drugs, New Delivery Systems in Parkinson's Disease.

Gupta HV, Lyons KE, Pahwa R.

Drugs Aging. 2019 Sep;36(9):807-821. doi: 10.1007/s40266-019-00682-9. Review.

PMID:
31161581
3.

Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.

Lyons KE, Pahwa R, Hermanowicz N, Davis T, Pagan F, Isaacson S.

Expert Rev Clin Pharmacol. 2019 Jul;12(7):681-691. doi: 10.1080/17512433.2019.1623669. Epub 2019 Jun 13. Review.

PMID:
31159608
4.

MDS evidence-based review of treatments for essential tremor.

Ferreira JJ, Mestre TA, Lyons KE, Benito-León J, Tan EK, Abbruzzese G, Hallett M, Haubenberger D, Elble R, Deuschl G; MDS Task Force on Tremor and the MDS Evidence Based Medicine Committee.

Mov Disord. 2019 Jul;34(7):950-958. doi: 10.1002/mds.27700. Epub 2019 May 2. Review.

PMID:
31046186
5.

Extended-Release Amantadine for Levodopa-Induced Dyskinesia.

Dashtipour K, Tafreshi AR, Pahwa R, Lyons KE.

Expert Rev Neurother. 2019 Apr;19(4):293-299. doi: 10.1080/14737175.2019.1592677. Epub 2019 Mar 20.

PMID:
30892103
6.

Deep brain stimulation of the subthalamic nucleus in Parkinson's disease patients over 75 years of age.

Sharma VD, Lyons KE, Nazzaro JM, Pahwa R.

J Neurol Sci. 2019 Apr 15;399:57-60. doi: 10.1016/j.jns.2019.02.019. Epub 2019 Feb 11.

PMID:
30772762
7.

Effects of Qigong Exercise on Non-Motor Symptoms and Inflammatory Status in Parkinson's Disease: A Protocol for a Randomized Controlled Trial.

Moon S, Sarmento CVM, Smirnova IV, Colgrove Y, Lyons KE, Lai SM, Liu W.

Medicines (Basel). 2019 Jan 18;6(1). pii: E13. doi: 10.3390/medicines6010013.

8.

What predicts falls in Parkinson disease?: Observations from the Parkinson's Foundation registry.

Parashos SA, Bloem BR, Browner NM, Giladi N, Gurevich T, Hausdorff JM, He Y, Lyons KE, Mari Z, Morgan JC, Post B, Schmidt PN, Wielinski CL.

Neurol Clin Pract. 2018 Jun;8(3):214-222. doi: 10.1212/CPJ.0000000000000461. Erratum in: Neurol Clin Pract. 2018 Aug;8(4):278.

9.

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease.

Sharma VD, Lyons KE, Pahwa R.

Ther Clin Risk Manag. 2018 Apr 12;14:665-673. doi: 10.2147/TCRM.S144481. eCollection 2018. Review.

10.

Pupillary Response to Cognitive Demand in Parkinson's Disease: A Pilot Study.

Kahya M, Moon S, Lyons KE, Pahwa R, Akinwuntan AE, Devos H.

Front Aging Neurosci. 2018 Apr 10;10:90. doi: 10.3389/fnagi.2018.00090. eCollection 2018.

11.

Symptomatic, non-infectious, non-hemorrhagic edema after subthalamic nucleus deep brain stimulation surgery for Parkinson's disease.

Nazzaro JM, Pahwa R, Lyons KE.

J Neurol Sci. 2017 Dec 15;383:42-46. doi: 10.1016/j.jns.2017.10.003. Epub 2017 Oct 12.

PMID:
29246619
12.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.

Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ.

JAMA Neurol. 2017 Aug 1;74(8):941-949. doi: 10.1001/jamaneurol.2017.0943.

13.

Pelvic Organ Prolapse Stage and the Relationship to Genital Hiatus and Perineal Body Measurements.

Dunivan GC, Lyons KE, Jeppson PC, Ninivaggio CS, Komesu YM, Alba FM, Rogers RG.

Female Pelvic Med Reconstr Surg. 2016 Nov/Dec;22(6):497-500.

14.

Deep brain stimulation for Parkinson's disease: current status and future outlook.

Smith KA, Pahwa R, Lyons KE, Nazzaro JM.

Neurodegener Dis Manag. 2016 Aug;6(4):299-317. doi: 10.2217/nmt-2016-0012. Epub 2016 Jul 13. Review.

PMID:
27409150
15.

Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations.

Perez-Lloret S, Ciampi de Andrade D, Lyons KE, Rodríguez-Blázquez C, Chaudhuri KR, Deuschl G, Cruccu G, Sampaio C, Goetz CG, Schrag A, Martinez-Martin P, Stebbins G; Members of the MDS Committee on Rating Scales Development.

Mov Disord Clin Pract. 2016 Jun 24;3(6):527-537. doi: 10.1002/mdc3.12384. eCollection 2016 Nov-Dec.

16.

Transducer-based evaluation of tremor.

Haubenberger D, Abbruzzese G, Bain PG, Bajaj N, Benito-León J, Bhatia KP, Deuschl G, Forjaz MJ, Hallett M, Louis ED, Lyons KE, Mestre TA, Raethjen J, Stamelou M, Tan EK, Testa CM, Elble RJ.

Mov Disord. 2016 Sep;31(9):1327-36. doi: 10.1002/mds.26671. Epub 2016 Jun 6. Review.

17.

Outpatient titration of carbidopa/levodopa enteral suspension (Duopa).

Pahwa R, Lyons KE.

Int J Neurosci. 2017 May;127(5):459-465. doi: 10.1080/00207454.2016.1193862. Epub 2016 Jun 21.

PMID:
27222011
18.

The characterization of a base-width neutral step as the first step for balance recovery in moderate Parkinson's disease.

McVey MA, Barnds AN, Lyons KE, Pahwa R, Mahnken JD, Luchies CW.

Int J Neurosci. 2016 Aug;126(8):713-22. doi: 10.3109/00207454.2015.1094472. Epub 2015 Oct 15.

PMID:
26371386
19.

Validation of the QUEST for German-speaking countries.

Hopfner F, Nebel A, Lyons KE, Tröster AI, Kuhlenbäumer G, Deuschl G, Martinez-Martin P.

Int J Neurosci. 2016;126(2):127-34. doi: 10.3109/00207454.2015.1077241. Epub 2015 Aug 25.

PMID:
26327253
20.

MDS-UPDRS to assess non-motor symptoms after STN DBS for Parkinson's disease.

Jafari N, Pahwa R, Nazzaro JM, Arnold PM, Lyons KE.

Int J Neurosci. 2016;126(1):25-9. doi: 10.3109/00207454.2015.1065257. Epub 2015 Aug 18.

PMID:
26134878
21.

Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.

Hanna-Pladdy B, Pahwa R, Lyons KE.

J Int Neuropsychol Soc. 2015 Apr;21(4):259-70. doi: 10.1017/S1355617715000181. Epub 2015 Apr 29.

22.

Proceedings of the Second Annual Deep Brain Stimulation Think Tank: What's in the Pipeline.

Gunduz A, Morita H, Rossi PJ, Allen WL, Alterman RL, Bronte-Stewart H, Butson CR, Charles D, Deckers S, de Hemptinne C, DeLong M, Dougherty D, Ellrich J, Foote KD, Giordano J, Goodman W, Greenberg BD, Greene D, Gross R, Judy JW, Karst E, Kent A, Kopell B, Lang A, Lozano A, Lungu C, Lyons KE, Machado A, Martens H, McIntyre C, Min HK, Neimat J, Ostrem J, Pannu S, Ponce F, Pouratian N, Reymers D, Schrock L, Sheth S, Shih L, Stanslaski S, Steinke GK, Stypulkowski P, Tröster AI, Verhagen L, Walker H, Okun MS.

Int J Neurosci. 2015;125(7):475-85. doi: 10.3109/00207454.2014.999268. Epub 2015 May 25. Review.

23.

Introspection on uncertainty and judicious help-seeking during the preschool years.

Coughlin C, Hembacher E, Lyons KE, Ghetti S.

Dev Sci. 2015 Nov;18(6):957-71. doi: 10.1111/desc.12271. Epub 2014 Dec 7.

PMID:
25483236
24.

Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.

Guthikonda LN, Lyons KE, Pahwa R.

J Comp Eff Res. 2014 Jul;3(4):331-3. doi: 10.2217/cer.14.33.

PMID:
25275230
25.

Qigong exercise may improve sleep quality and gait performance in Parkinson's disease: a pilot study.

Wassom DJ, Lyons KE, Pahwa R, Liu W.

Int J Neurosci. 2015;125(8):578-84. doi: 10.3109/00207454.2014.966820. Epub 2014 Oct 22.

PMID:
25233147
26.

Treatment of early Parkinson's disease.

Pahwa R, Lyons KE.

Curr Opin Neurol. 2014 Aug;27(4):442-9. doi: 10.1097/WCO.0000000000000113. Review.

PMID:
24950010
27.

Peptidoglycan recognition protein genes and risk of Parkinson's disease.

Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, Umbach DM, Bhudhikanok GS, Meng C, Korell M, Comyns K, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Sandler DP, Langston JW, Tanner CM.

Mov Disord. 2014 Aug;29(9):1171-80. doi: 10.1002/mds.25895. Epub 2014 May 17.

28.

A Comparative White Matter Study with Parkinson's disease, Parkinson's Disease with Dementia and Alzheimer's Disease.

Perea RD, Rada RC, Wilson J, Vidoni1 ED, Morris JK, Lyons KE, Pahwa R, Burns JM, Honea RA.

J Alzheimers Dis Parkinsonism. 2013 Aug 26;3:123.

29.

Heralding the authoritarian? Orientation toward authority in early childhood.

Reifen Tagar M, Federico CM, Lyons KE, Ludeke S, Koenig MA.

Psychol Sci. 2014 Apr;25(4):883-92. doi: 10.1177/0956797613516470. Epub 2014 Feb 6.

PMID:
24503871
30.

Mobility, mood and site of care impact health related quality of life in Parkinson's disease.

Nutt JG, Siderowf AD, Guttman M, Schmidt PN, Zamudio JI, Wu SS, Okun MS, Simuni T, Parashos SA, Dahodwala NA, Davis TL, Giladi N, Gurevich T, Hauser RA, Jankovic J, Lyons KE, Marsh L, Miyasaki JM, Morgan JC, Santiago AJ, Tarsy D, Mari Z, Malaty IA, Nelson EC; National Parkinson Foundation Quality Improvement Initiative Investigators.

Parkinsonism Relat Disord. 2014 Mar;20(3):274-9. doi: 10.1016/j.parkreldis.2013.10.004. Epub 2013 Oct 16.

PMID:
24182524
31.

Deep brain stimulation for essential tremor.

Nazzaro JM, Lyons KE, Pahwa R.

Handb Clin Neurol. 2013;116:155-66. doi: 10.1016/B978-0-444-53497-2.00013-9.

PMID:
24112892
32.

Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.

Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, Hsu A, O'Connell M, Kell S, Gupta S; APEX-PD Investigators.

Parkinsonism Relat Disord. 2014 Feb;20(2):142-8. doi: 10.1016/j.parkreldis.2013.08.017. Epub 2013 Sep 5.

33.

Deep brain stimulation lead-contact heating during 3T MRI: single- versus dual-channel pulse generator configurations.

Nazzaro JM, Klemp JA, Brooks WM, Cook-Wiens G, Mayo MS, Van Acker GM 3rd, Lyons KE, Cheney PD.

Int J Neurosci. 2014 Mar;124(3):166-74. doi: 10.3109/00207454.2013.840303. Epub 2013 Oct 8.

PMID:
24000873
34.

Treatment of motor and NMS of Parkinson's disease with the rotigotine transdermal system.

Lyons KE.

Neurol Clin. 2013 Aug;31(3 Suppl):vii-ix. doi: 10.1016/j.ncl.2013.04.014. Epub 2013 Jun 14. No abstract available.

35.

Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.

Lyons KE, Pahwa R.

Neurol Clin. 2013 Aug;31(3 Suppl):S51-9. doi: 10.1016/j.ncl.2013.04.011. Epub 2013 Jun 14. Review.

36.

Memory for child sexual abuse information: simulated memory error and individual differences.

McWilliams K, Goodman GS, Lyons KE, Newton J, Avila-Mora E.

Mem Cognit. 2014 Jan;42(1):151-63. doi: 10.3758/s13421-013-0345-2.

PMID:
23835600
37.

Predictors of mild cognitive impairment in early-stage Parkinson's disease.

Hanna-Pladdy B, Jones K, Cabanban R, Pahwa R, Lyons KE.

Dement Geriatr Cogn Dis Extra. 2013 May 18;3(1):168-78. doi: 10.1159/000351421. Print 2013 Jan.

38.

The effect of moderate Parkinson's disease on compensatory backwards stepping.

McVey MA, Amundsen S, Barnds A, Lyons KE, Pahwa R, Mahnken JD, Luchies CW.

Gait Posture. 2013 Sep;38(4):800-5. doi: 10.1016/j.gaitpost.2013.03.028. Epub 2013 Apr 20.

PMID:
23607994
39.

I don't want to pick! Introspection on uncertainty supports early strategic behavior.

Lyons KE, Ghetti S.

Child Dev. 2013 Mar-Apr;84(2):726-36. doi: 10.1111/cdev.12004. Epub 2012 Dec 22.

PMID:
23278486
40.

Long-term benefits in quality of life after unilateral thalamic deep brain stimulation for essential tremor.

Nazzaro JM, Pahwa R, Lyons KE.

J Neurosurg. 2012 Jul;117(1):156-61. doi: 10.3171/2012.3.JNS112316. Epub 2012 Apr 20.

PMID:
22519432
41.

The UPDRS-8: a brief clinical assessment scale for Parkinson's disease.

Hauser RA, Lyons KE, Pahwa R.

Int J Neurosci. 2012 Jul;122(7):333-7. doi: 10.3109/00207454.2012.657381. Epub 2012 Feb 23.

PMID:
22329569
42.

Head injury, α-synuclein Rep1, and Parkinson's disease.

Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, Marras C, Hauser RA, Jankovic J, Factor SA, Bressman S, Lyons KE, Meng C, Korell M, Roucoux DF, Hoppin JA, Sandler DP, Langston JW, Tanner CM.

Ann Neurol. 2012 Jan;71(1):40-8. doi: 10.1002/ana.22499.

43.

Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial.

Okun MS, Gallo BV, Mandybur G, Jagid J, Foote KD, Revilla FJ, Alterman R, Jankovic J, Simpson R, Junn F, Verhagen L, Arle JE, Ford B, Goodman RR, Stewart RM, Horn S, Baltuch GH, Kopell BH, Marshall F, Peichel D, Pahwa R, Lyons KE, Tröster AI, Vitek JL, Tagliati M; SJM DBS Study Group.

Lancet Neurol. 2012 Feb;11(2):140-9. doi: 10.1016/S1474-4422(11)70308-8. Epub 2012 Jan 11. Erratum in: Lancet Neurol. 2012 Mar;11(3):208.

PMID:
22239915
44.

Selective left, right and bilateral stimulation of subthalamic nuclei in Parkinson's disease: differential effects on motor, speech and language function.

Schulz GM, Hosey LA, Bradberry TJ, Stager SV, Lee LC, Pawha R, Lyons KE, Metman LV, Braun AR.

J Parkinsons Dis. 2012;2(1):29-40. doi: 10.3233/JPD-2012-11049.

PMID:
23939406
45.

Long-term evaluation of gait initiation in six Parkinson's disease patients with bilateral subthalamic stimulation.

Muniz AM, Nadal J, Lyons KE, Pahwa R, Liu W.

Gait Posture. 2012 Mar;35(3):452-7. doi: 10.1016/j.gaitpost.2011.11.006. Epub 2011 Dec 7.

PMID:
22154114
46.

The impact and management of nonmotor symptoms of Parkinson's disease.

Lyons KE, Pahwa R.

Am J Manag Care. 2011 Oct;17 Suppl 12:S308-14. Review.

47.

Diagnosis and initiation of treatment in Parkinson's disease.

Lyons KE, Pahwa R.

Int J Neurosci. 2011;121 Suppl 2:27-36. doi: 10.3109/00207454.2011.620197. Review.

PMID:
22035027
48.

Current issues in the diagnosis and treatment of Parkinson's disease. Introduction.

Pahwa R, Lyons KE.

Int J Neurosci. 2011;121 Suppl 2:1-2. doi: 10.3109/00207454.2011.622454. No abstract available.

PMID:
22035023
49.

The importance of testing deep brain stimulation lead impedances before final lead implantation.

Nazzaro JM, Lyons KE, Pahwa R, Ridings LW.

Surg Neurol Int. 2011;2:131. doi: 10.4103/2152-7806.85473. Epub 2011 Sep 27.

50.

Common and unique responses to dopamine agonist therapy and deep brain stimulation in Parkinson's disease: an H(2)(15)O PET study.

Bradberry TJ, Metman LV, Contreras-Vidal JL, van den Munckhof P, Hosey LA, Thompson JL, Schulz GM, Lenz F, Pahwa R, Lyons KE, Braun AR.

Brain Stimul. 2012 Oct;5(4):605-15. doi: 10.1016/j.brs.2011.09.002. Epub 2011 Oct 5.

Supplemental Content

Loading ...
Support Center